Abstract:Background A higher circulating plasma ceramide ratio (C16:0/C24:0) is associated with an increased risk of heart failure, even after accounting for standard risk factors including lipid markers. However, the pathobiological mechanisms that underlie this association are incompletely understood. We tested the hypothesis that plasma ceramide ratio (C16:0/C24:0) is associated with adverse cardiac remodeling in the community. Methods and Results We evaluated 2652 Framingham Offspring Study participants (mean age, 66±9 years; 55% women) who attended their eighth examination cycle and underwent routine echocardiography and liquid chromatography–tandem mass spectrometry–based assays for circulating ceramide concentrations. We used multivariable linear regression models to relate C16:0/C24:0 (independent variable) to the following echocardiographic measures (dependent variables; separate models for each): left ventricular mass, left ventricular ejection fraction, left atrial emptying fraction, left atrial end‐systolic volume, E/e′ (a measure of left ventricular diastolic function), and left ventricular global circumferential and longitudinal strain by speckle‐tracking echocardiography. In multivariable‐adjusted analyses, higher C16:0/C24:0 per standard deviation increment was associated with lower left ventricular ejection fraction (0.991‐fold change in left ventricular ejection fraction; P =0.0004), worse global circumferential strain (β=0.34, P =0.004), higher left atrial end‐systolic volume (β=2.48, p<0.0001), and lower left atrial emptying fraction (0.99‐fold change; P <0.0001). The C16:0/C24:0 ratio was not associated with either E/e′ or global longitudinal strain, and the association with higher left ventricular mass was rendered statistically nonsignificant upon correction for multiple comparisons. Conclusions Our cross‐sectional observations in a large community‐based sample are consistent with a potential detrimental impact of higher ceramide ratio (C16:0/24:0) on cardiac remodeling traits, which may partly explain the associations of these molecular species with clinical heart failure. Clinical Perspective What Is New? We used a high‐throughput liquid chromatography–mass spectrometry assay to quantify ratios of ceramide molecular species in the plasma and subsequently assessed their relations to echocardiographic measures of cardiac remodeling. Data from the Framingham Offspring Study demonstrate that higher plasma ceramide ratio (C16:0/24:0) is associated with potentially detrimental changes in echocardiographic measures of cardiac structure and function. What Are the Clinical Implications? Our study observations support the notion that the association between higher ceramide ratio (C16:0/24:0) and the subsequently increased risk of clinical heart failure may be partly explained by relations with unfavorable subclinical cardiac structural and functional alterations. Introduction Heart failure (HF) remains a leading cause of morbidity and mortality, affecting 6.5 million Americans, and its prevalence is expected to rise with the aging of the US population. 1 Given the substantial and rising burden of HF, ongoing efforts are needed to uncover novel mechanistic pathways that may underlie disease pathogenesis and progression. One area of recent interest is the role of plasma ceramide biomarkers in the pathogenesis of cardiovascular disease (CVD), including HF. Ceramides are bioactive lipids with a sphingoid base and a fatty acyl chain that are present in cell membranes and plasma, and have major influences on cellular signaling, differentiation, senescence, and programmed cell death. 2 Ceramide synthases facilitate variable acetylation of the sphingoid base, producing a spectrum of ceramide molecular species. 2 Expression and biomolecular effects of ceramides can vary on the basis of detectable relative proportions of distinct circulating ceramide species and the CVD risk profile. 3 Recent studies have focused, therefore, on analyzing the ratio of select ceramides, such as the ratio of long‐chain to very‐long‐chain ceramide species. 4 , <a class="tab-link" hre -Abstract Truncated-

Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study

Plasma Ceramides Are Elevated in Obese Subjects with Type 2 Diabetes and Correlate with the Severity of Insulin Resistance.

Effect of circulating ceramides on adiposity and insulin resistance in patients with type 2 diabetes: An observational cross‐sectional study

Elevated serum ceramides are linked with obesity-associated gut dysbiosis and impaired glucose metabolism

Ceramides—Emerging Biomarkers of Lipotoxicity in Obesity, Diabetes, Cardiovascular Diseases, and Inflammation

Plasma Ceramides and Other Sphingolipids in Relation to Incident Prediabetes in a Longitudinal Biracial Cohort

Plasma Ceramides Predict All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes

Insulin resistance induced by de novo pathway-generated C16-ceramide is associated with type 2 diabetes in an obese population

Plasma ceramides as biomarkers for microvascular disease and clinical outcomes in diabetes and myocardial infarction

Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study

Improved Insulin Sensitivity after Exercise Training is Linked to Reduced Plasma C14:0 Ceramide in Obesity and Type 2 Diabetes.

Associations of NAFLD with circulating ceramides and impaired glycemia

Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology

Association of Circulating Ceramides With Cardiac Structure and Function in the Community: The Framingham Heart Study.

Ceramides as the molecular link between impaired lipid metabolism, saturated fatty acid intake and insulin resistance: are all saturated fatty acids to be blamed for ceramide-mediated lipotoxicity?

Ceramides are early responders in metabolic syndrome development in rhesus monkeys

Plasma ceramides are elevated in overweight Holstein dairy cows experiencing greater lipolysis and insulin resistance during the transition from late pregnancy to early lactation.

The relationship between ceramide profile and residual inflammatory risk in patients with coronary artery disease: Insights from an prospective study

Associations between plasma ceramides and mortality in patients with coronary artery disease

Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: A population-based cohort study in China

Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes